EUVIMEDEUVIMED entdecken
Crossref

Design and Synthesis of Pyrazolomorphinan Derivatives as Novel Delta Opioid Receptor Agonists

Hideaki Fujii iD, Chiharu Iwamatsu, Saki Ishizaki, Hideki Nakamura, Daisuke Yamada, Shuma Yamada, Junichi Niwa, Toshinori Yoshioka, Pengfei Liu, Shintaro Shirakura, Fumika Karaki iD, Shigeto Hirayama und 1 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c02499 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Hideaki Fujii und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University, 5-9-1, Shirokane, Minato-ku, Tokyo 108-8641, Japan. Hauptthemen laut MEDLINE: Receptors, Opioid, delta, Drug Design, Morphinans, Pyrazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Nippon Chemiphar Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We designed pyrazolomorphinan derivatives 3 as novel δ opioid receptor (DOR) selective agonists with an unprecedented chemotype according to the drug design concept for the DOR selective agonist KNT-127 which encompassed the message-address concept, the accessory site concept, and the conversion of an indole ring into a quinoline ring. The designed compounds 3 as well as their regioisomers 9 showed potent DOR agonistic activities with low or almost no activities for the μ (MOR) and κ opioid receptors (KOR). Among the tested compounds, SYK-1106 (9j) bearing a cyclohexyl substituent was the most potent and efficacious DOR agonist (DOR: EC50 = 0.089 nM, Emax = 111%; agonistic activities for the MOR and KOR were not determined). SYK-1106 showed dose-dependent and DOR antagonist NTI reversible antidepressant-like effects at 0.3 mg/kg, s.c. in the mouse forced-swimming tests without an effect on locomotor activity and with no convulsive effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Opioid, deltaDrug DesignMorphinansPyrazolesAntidepressive AgentsAnimalsMiceStructure-Activity RelationshipMaleHumansReceptors, Opioid, kappa

Substanzen

Receptors, Opioid, deltaMorphinansPyrazolesAntidepressive AgentsReceptors, Opioid, kappa

Autor:innen und Institutionen

  • Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University, 5-9-1, Shirokane, Minato-ku, Tokyo 108-8641, Japan.
  • Medicinal Research Laboratories, School of Pharmacy, Kitasato University, 5-9-1, Shirokane, Minato-ku, Tokyo 108-8641, Japan.
  • Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., 1-22, Hikokawado, Misato, Saitama 341-0005, Japan.
  • Laboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba 278-8510, Japan.

ORCID-Profile: Hideaki Fujii, Fumika Karaki

Förderung

  • Nippon Chemiphar Co., Ltd.

Zitieren

APA

Fujii, H., Iwamatsu, C., Ishizaki, S., Nakamura, H., Yamada, D., Yamada, S., Niwa, J., Yoshioka, T., Liu, P., Shirakura, S., Karaki, F., Hirayama, S., & Saitoh, A. (2025). Design and Synthesis of Pyrazolomorphinan Derivatives as Novel Delta Opioid Receptor Agonists. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02499

Vancouver

Fujii H, Iwamatsu C, Ishizaki S, Nakamura H, Yamada D, Yamada S, et al. Design and Synthesis of Pyrazolomorphinan Derivatives as Novel Delta Opioid Receptor Agonists. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02499

BibTeX
@article{Fujii2025,
  author = {Fujii, Hideaki and Iwamatsu, Chiharu and Ishizaki, Saki and Nakamura, Hideki and Yamada, Daisuke and Yamada, Shuma and Niwa, Junichi and Yoshioka, Toshinori and Liu, Pengfei and Shirakura, Shintaro and Karaki, Fumika and Hirayama, Shigeto and Saitoh, Akiyoshi},
  title = {Design and Synthesis of Pyrazolomorphinan Derivatives as Novel Delta Opioid Receptor Agonists},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c02499}
}
Kostenlos starten →